Juno Therapeutics, Inc. (NASDAQ: JUNO) Shareholder Lawsuit

Our law firm is investigating potential claims on behalf of shareholders of Juno Therapeutics, Inc. (NASDAQ: JUNO) over possible violations of US securities laws.

If you have purchased Juno Therapeutics, Inc. (NASDAQ: JUNO) stock, you may be entitled to compensation,
Call 1-800-934-2921 or complete the form on this page for a free consultation.

Our law firm is investigating potential claims on behalf of shareholders of Juno Therapeutics, Inc. (NASDAQ: JUNO) over possible violations of US securities laws due to possible breaches of fiduciary duty by officers of the company. If you have purchased shares of Juno Therapeutics, Inc. (NASDAQ: JUNO), contact our law firm right now to protect your rights.

According to a recent lawsuit, JUNO executives may have misled investors about the prospects of a new cancer drug, JCAR015. The lawsuit alleges that JUNO knew about serious problems with the safety of this drug that arose during clinical trials, yet continued to promote this drug as highly promising to investors, thereby inflating the value of JUNO shares.

Additionally, the JUNO lawsuit alleges that officers of the company may have been improperly compensated. Specifically, the lawsuit alleges that certain company officers received compensation packages that greatly exceeded industry averages for their position.

Own shares of Juno Therapeutics, Inc. (NASDAQ: JUNO)? Contact us to protect your rights. – Juno Therapeutics, Inc. (NASDAQ: JUNO) Investor Lawsuit

If you have purchased shares of Juno Therapeutics, Inc. (NASDAQ: JUNO), complete the form on this page or call 1-800-934-2921 right now to protect your rights.

Written by

Comments are closed.